Skip to main content
Caplight Logo









Draupnir Bio

Draupnir Bio

Private
CopenhagenHealthcare & Life Scienceshttps://draupnir.bio/

Last Round

Seed

Jul 17, 2024

Total Funding Raised

$48.91M

Company Overview

Draupnir Bio is a biotechnology company that develops oral, small molecule degraders of extracellular disease-causing proteins by harnessing the natural machinery of the lysosome.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share

AI Layer

Non-AI

Keywords

targeted protein degradationextracellular protein degradationSORTACsmall molecule degradersTPDoral protein degradersundruggable targetslysosome targeting chimeraLYTACdrug discovery platformmembrane protein degradationsortilinpreclinical pipeline

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Draupnir Bio Comparables

Compare Draupnir Bio with similar companies based on industry and business-model similarity.

Draupnir Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Avilar Therapeutics
82%
Lycia Therapeutics
79%
Cullgen
76%

Draupnir Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedJul 17, 2024
Series AOct 1, 2019
GrantNov 30, 2017
SeedApr 1, 2017

Key People

Founding team and executive leadership

Andrew Hotchkiss

Chief Executive Officer

Executive Team

Draupnir Bio Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 17, 2024

    $13.1M round led by MP Healthcare and The Export and Investment Fund of Denmark.

  • Oct 1, 2019

    $33M round led by Gilde Healthcare, High-Tech Gründerfonds, Inkef Capital, and novoholdings.

Draupnir Bio Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Draupnir Bio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Draupnir Bio's valuation, stock price, and market status.

Firmographic Details

HeadquartersCopenhagen
Employee Range16
Year Founded2017
Last FundingJul 17, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?